Second Quarter Highlights:
ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2024.
"In the second quarter, we continued to make substantial progress on our strategic growth initiatives to drive sustained and profitable growth, and we further solidified our position as the leader in the aortic disease space. Revenue growth in the second quarter was driven by year-over-year constant currency growth in On-X of 15% and stent grafts of 13%, both compared to the second quarter of 2023. We also saw continued revenue strength across Latin America and Asia Pacific, which grew 25% and 15%, respectively, in the second quarter on a constant currency basis compared to the same period last year. In addition to our strong revenue performance, adjusted EBITDA grew 35% this quarter, demonstrating our ability to scale the business and continue to expand adjusted EBITDA margins," said Pat Mackin, Chairman, President, and Chief Executive Officer.
Mr. Mackin concluded, "Given our second quarter performance, we are raising our full year revenue and adjusted EBITDA expectations for 2024."
Second Quarter 2024 Financial Results
Total revenues for the second quarter of 2024 were $98.0 million, an increase of 10% on both a GAAP basis and constant currency basis, both compared to the second quarter of 2023.
Net loss for the second quarter of 2024 was ($2.1) million, or ($0.05) per fully diluted common share, compared to net loss of ($3.4) million, or ($0.08) per fully diluted common share for the second quarter of 2023. Non-GAAP net income for the second quarter of 2024 was $2.9 million, or $0.07 per fully diluted common share, compared to non-GAAP net income of $2.3 million, or $0.06 per fully diluted common share for the second quarter of 2023. Non-GAAP net income for the second quarter of 2024 includes pretax losses related to foreign currency revaluation of $0.9 million.
2024 Financial Outlook
Artivion is raising its revenue guidance range and now expects constant currency revenue growth of between 10% to 12% for the full year 2024, compared to the 9% to 12% previously provided. Growth rates are compared to 2023. The Company expects revenues to be in the range of $388 to $396 million compared to the previously articulated range of $386 to $396 million. At current rates, the Company expects negligible year-over-year currency impact on the full year 2024 revenues.
Additionally, Artivion is raising its adjusted EBITDA guidance range and now expects growth of between 28% and 34% for the full year 2024, compared to the 26% to 34% previously provided. Growth rates are compared to 2023. The Company expects adjusted EBITDA to be in the range of $69 to $72 million compared to the previously articulated range of $68 to $72 million.
The Company's financial performance for 2024 and future periods is subject to the risks identified below.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including non-GAAP revenue, non-GAAP net income, non-GAAP adjusted EBITDA, non-GAAP general, administrative, and marketing expenses, and free cash flows. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with US GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company's non-GAAP revenues are adjusted for the impact of changes in currency exchange. The Company's non-GAAP net income, non-GAAP adjusted EBITDA, non-GAAP general, administrative, and marketing, and free cash flows results exclude (as applicable) depreciation and amortization expense, interest income and expense, stock-based compensation expense, loss or gain on foreign currency revaluation, income tax expense or benefit, corporate rebranding expense, business development, integration, and severance income or expense, loss on extinguishment of debt, and non-cash interest expense. The Company generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Company management believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions, the operating expense structure of the Company's existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses, and the transaction and integration expenses incurred in connection with recently acquired and divested product lines, and the operating expense structure excluding fluctuations resulting from foreign currency revaluation and stock-based compensation expense. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as impact of recent acquisitions, non-cash expense related to amortization of previously acquired tangible and intangible assets, and any related adjustments to their carrying values. The Company has adjusted for the impact of changes in currency exchange from certain revenues to evaluate comparable product growth rates on a constant currency basis. The Company does, however, expect to incur similar types of expenses and currency exchange impacts in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur. Company management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety, including the reconciliation of GAAP to non-GAAP financial measures.
Webcast and Conference Call Information
The company will hold a teleconference call and live webcast on August 8, 2024, at 4:30 p.m. ET to discuss the results, followed by a question and answer session. To participate in the conference call dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13746922.
The live webcast and replay can be accessed by going to the Investors section of the Artivion website at www.Artivion.com and selecting the heading Webcasts & Presentations.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.
Forward Looking-Statements
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include, but are not limited to, those regarding our full year revenue expectations and our confidence in our ability to meet or exceed our adjusted EBITDA target for 2024; the timeline for regulatory approval for AMDS and other products; that our revenues for the full year 2024 will be in the range of $388 and $396 million, representing revenue growth of between 10% to 12% compared to 2023 on a constant currency basis; expect, at current exchange rates, negligible currency impact on the 2024 full year revenues; and expect non-GAAP adjusted EBITDA to increase between 28% and 34% for the full year 2024 compared to 2023, resulting in non-GAAP adjusted EBITDA in the range of $69 to $72 million in 2024. These forward-looking statements are subject to a number of risks, uncertainties, estimates and assumptions that may cause actual results to differ materially from current expectations, including, but not limited to, the unpredictability of the timing and outcome of regulatory decisions, the benefits anticipated from the Ascyrus Medical LLC transaction and Endospan agreements and our operational improvements in our tissue and stent graft business may not be achieved at all or at the levels we anticipate or had originally anticipated; the benefits anticipated from our clinical trials and regulatory approvals may not be achieved or achieved on our anticipated timelines; and the benefits anticipated from our expansion into APAC and LATAM may not be achieved or achieved on our anticipated timelines. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2023, and our Form 10-Q for the quarter ended June 30, 2024. Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.
Artivion, Inc. and Subsidiaries
| |||||||
Three Months Ended | Six Months Ended | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Revenues: | |||||||
Products | $ 73,210 | $ 66,003 | $ 144,324 | $ 128,294 | |||
Preservation services | 24,809 | 23,248 | 51,126 | 44,186 | |||
Total revenues | 98,019 | 89,251 | 195,450 | 172,480 | |||
Cost of products and preservation services: | |||||||
Products | 24,545 | 20,977 | 48,295 | 40,510 | |||
Preservation services | 10,150 | 10,190 | 20,885 | 20,159 | |||
Total cost of products and preservation services | 34,695 | 31,167 | 69,180 | 60,669 | |||
Gross margin | 63,324 | 58,084 | 126,270 | 111,811 | |||
Operating expenses: | |||||||
General, administrative, and marketing | 49,320 | 57,241 | 80,009 | 107,606 | |||
Research and development | 7,497 | 7,418 | 14,443 | 14,641 | |||
Total operating expenses | 56,817 | 64,659 | 94,452 | 122,247 | |||
Gain from sale of non-financial assets | — | (14,250) | — | (14,250) | |||
Operating income | 6,507 | 7,675 | 31,818 | 3,814 | |||
Interest expense | 8,304 | 6,356 | 16,130 | 12,452 | |||
Interest income | (353) | (265) | (727) | (340) | |||
Loss on extinguishment of debt | — | — | 3,669 | — | |||
Other expense, net | 983 | 4,241 | 2,392 | 3,278 | |||
(Loss) income before income taxes | (2,427) | (2,657) | 10,354 | (11,576) | |||
Income tax (benefit) expense | (306) | 725 | 4,942 | 5,338 | |||
Net (loss) income | $ (2,121) | $ (3,382) | $ 5,412 | $ (16,914) | |||
(Loss) income per share: | |||||||
Basic | $ (0.05) | $ (0.08) | $ 0.13 | $ (0.41) | |||
Diluted | $ (0.05) | $ (0.08) | $ 0.13 | $ (0.41) | |||
Weighted-average common shares outstanding: | |||||||
Basic | 41,683 | 40,755 | 41,487 | 40,595 | |||
Diluted | 41,683 | 40,755 | 42,405 | 40,595 | |||
Net (loss) income | $ (2,121) | $ (3,382) | $ 5,412 | $ (16,914) | |||
Other comprehensive (loss) income: | |||||||
Foreign currency translation adjustments | (2,727) | 1,026 | (5,864) | $ 5,647 | |||
Unrealized gain (loss) from foreign currency intra-entity loans, net of tax | 404 | 800 | 2,013 | (205) | |||
Comprehensive (loss) income | $ (4,444) | $ (1,556) | $ 1,561 | $ (11,472) | |||
Artivion, Inc. and Subsidiaries
| |||
June 30, | December 31, | ||
(Unaudited) | |||
ASSETS | |||
Current assets: | |||
Cash and cash equivalents | $ 55,019 | $ 58,940 | |
Trade receivables, net | 73,890 | 71,796 | |
Other receivables | 5,063 | 2,342 | |
Inventories, net | 80,802 | 81,976 | |
Deferred preservation costs, net | 50,674 | 49,804 | |
Prepaid expenses and other | 19,514 | 15,810 | |
Total current assets | 284,962 | 280,668 | |
Goodwill | 244,008 | 247,337 | |
Acquired technology, net | 135,151 | 142,593 | |
Operating lease right-of-use assets, net | 41,655 | 43,822 | |
Property and equipment, net | 37,440 | 38,358 | |
Other intangibles, net | 29,261 | 29,638 | |
Deferred income taxes | 3,309 | 1,087 | |
Other long-term assets | 13,753 | 8,894 | |
Total assets | $ 789,539 | $ 792,397 | |
LIABILITIES AND SHAREHOLDERS' EQUITY | |||
Current liabilities: | |||
Accounts payable | $ 11,728 | $ 13,318 | |
Accrued expenses | 16,490 | 12,732 | |
Accrued compensation | 13,995 | 18,715 | |
Current maturities of operating leases | 3,283 | 3,395 | |
Taxes payable | 1,734 | 3,840 | |
Accrued procurement fees | 1,472 | 1,439 | |
Current portion of long-term debt | 268 | 1,451 | |
Other current liabilities | 1,612 | 2,972 | |
Total current liabilities | 50,582 | 57,862 | |
Long-term debt | 313,295 | 305,531 | |
Contingent consideration | 48,210 | 63,890 | |
Non-current maturities of operating leases | 41,967 | 43,977 | |
Deferred income taxes | 21,719 | 21,851 | |
Deferred compensation liability | 7,455 | 6,760 | |
Non-current finance lease obligation | 3,202 | 3,405 | |
Other long-term liabilities | 8,053 | 7,341 | |
Total liabilities | $ 494,483 | $ 510,617 | |
Commitments and contingencies | |||
Shareholders' equity: | |||
Preferred stock | — | — | |
Common stock (75,000 shares authorized, 43,279 and 42,569 shares issued in 2024 and 2023, respectively) | 433 | 426 | |
Additional paid-in capital | 367,627 | 355,919 | |
Retained deficit | (42,495) | (47,907) | |
Accumulated other comprehensive loss | (15,861) | (12,010) | |
Treasury stock, at cost, 1,487 shares as of June 30, 2024 and December 31, 2023 | (14,648) | (14,648) | |
Total shareholders' equity | 295,056 | 281,780 | |
Total liabilities and shareholders' equity | $ 789,539 | $ 792,397 | |
Artivion, Inc. and Subsidiaries | |||
Six Months Ended | |||
2024 | 2023 | ||
Net cash flows from operating activities: | |||
Net income (loss) | $ 5,412 | $ (16,914) | |
Adjustments to reconcile net income (loss) to net cash from operating activities: | |||
Depreciation and amortization | 11,800 | 11,501 | |
Non-cash compensation | 7,730 | 7,279 | |
Non-cash lease expense | 3,897 | 3,631 | |
Loss on extinguishment of debt | 3,669 | — | |
Write-down of inventories and deferred preservation costs | 1,508 | 2,021 | |
Deferred income taxes | 994 | (8,073) | |
Fair value adjustment of long-term loan | — | 5,000 | |
Gain from sale of non-financial assets | — | (14,250) | |
Change in fair value of contingent consideration | (15,680) | 15,700 | |
Other | 1,178 | 1,836 | |
Changes in operating assets and liabilities: | |||
Inventories and deferred preservation costs | (2,165) | (6,921) | |
Prepaid expenses and other assets | (5,224) | (2,317) | |
Accounts payable, accrued expenses, and other liabilities | (6,031) | 1,607 | |
Receivables | (6,446) | 655 | |
Net cash flows provided by operating activities | 642 | 755 | |
Net cash flows from investing activities: | |||
Proceeds from sale of non-financial assets, net | — | 14,250 | |
Payments for Endospan Agreement | — | (5,000) | |
Capital expenditures | (6,124) | (5,015) | |
Net cash flows (used in) provided by investing activities | (6,124) | 4,235 | |
Net cash flows from financing activities: | |||
Proceeds from issuance of debt | 190,000 | — | |
Proceeds from revolving credit facility | 30,000 | — | |
Proceeds from exercise of stock options and issuance of common stock | 3,587 | 2,581 | |
Proceeds from financing insurance premiums | — | 3,558 | |
Principal payments on short-term notes payable | (1,027) | (529) | |
Payment of debt issuance costs | (10,044) | — | |
Repayment of debt | (211,688) | (1,381) | |
Other | (272) | (825) | |
Net cash flows provided by financing activities | 556 | 3,404 | |
Effect of exchange rate changes on cash and cash equivalents | 1,005 | 1,030 | |
(Decrease) increase in cash and cash equivalents | (3,921) | 9,424 | |
Cash and cash equivalents beginning of period | 58,940 | 39,351 | |
Cash and cash equivalents end of period | $ 55,019 | $ 48,775 | |
Artivion, Inc. and Subsidiaries
| |||||||
Three Months Ended | Six Months Ended | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Products: | |||||||
Aortic stent grafts | $ 32,190 | $ 28,359 | $ 64,293 | $ 54,509 | |||
On-X | 20,645 | 17,946 | 40,326 | 35,602 | |||
Surgical sealants | 18,545 | 16,566 | 35,526 | 33,269 | |||
Other | 1,830 | 3,132 | 4,179 | 4,914 | |||
Total products | 73,210 | 66,003 | 144,324 | 128,294 | |||
Preservation services | 24,809 | 23,248 | 51,126 | 44,186 | |||
Total revenues | $ 98,019 | $ 89,251 | $ 195,450 | $ 172,480 | |||
North America | 48,662 | 46,268 | 99,590 | 89,513 | |||
Europe, the Middle East, and Africa | 34,145 | 30,143 | 67,733 | 58,072 | |||
Asia Pacific | 9,653 | 8,375 | 17,262 | 16,253 | |||
Latin America | 5,559 | 4,465 | 10,865 | 8,642 | |||
Total revenues | $ 98,019 | $ 89,251 | $ 195,450 | $ 172,480 | |||
Artivion, Inc. and Subsidiaries
| |||||||||
Revenues for the Three Months Ended June 30, | Percent Change From Prior Year | ||||||||
2024 | 2023 | ||||||||
US GAAP | US GAAP | Exchange | Constant | Constant | |||||
Products: | |||||||||
Aortic stent grafts | $ 32,190 | $ 28,359 | $ 148 | $ 28,507 | 13 % | ||||
On-X | 20,645 | 17,946 | (3) | 17,943 | 15 % | ||||
Surgical sealants | 18,545 | 16,566 | — | 16,566 | 12 % | ||||
Other | 1,830 | 3,132 | (2) | 3,130 | -42 % | ||||
Total products | 73,210 | 66,003 | 143 | 66,146 | 11 % | ||||
Preservation services | 24,809 | 23,248 | (6) | 23,242 | 7 % | ||||
Total | $ 98,019 | $ 89,251 | $ 137 | $ 89,388 | 10 % | ||||
North America | 48,662 | 46,268 | (11) | 46,257 | 5 % | ||||
Europe, the Middle East, and Africa | 34,145 | 30,143 | 177 | 30,320 | 13 % | ||||
Asia Pacific | 9,653 | 8,375 | (1) | 8,374 | 15 % | ||||
Latin America | 5,559 | 4,465 | (28) | 4,437 | 25 % | ||||
Total | $ 98,019 | $ 89,251 | $ 137 | $ 89,388 | 10 % | ||||
Revenues for the Six Months Ended June 30, | Percent Change From Prior Year | ||||||||
2024 | 2023 | ||||||||
US GAAP | US GAAP | Exchange | Constant | Constant | |||||
Products: | |||||||||
Aortic stent grafts | $ 64,293 | $ 54,509 | 896 | $ 55,405 | 16 % | ||||
On-X | 40,326 | 35,602 | 101 | 35,703 | 13 % | ||||
Surgical sealants | 35,526 | 33,269 | 118 | 33,387 | 6 % | ||||
Other | 4,179 | 4,914 | 3 | 4,917 | -15 % | ||||
Total products | 144,324 | 128,294 | 1,118 | 129,412 | 12 % | ||||
Preservation services | 51,126 | 44,186 | (4) | 44,182 | 16 % | ||||
Total | $ 195,450 | $ 172,480 | $ 1,114 | $ 173,594 | 13 % | ||||
North America | 99,590 | 89,513 | (7) | 89,506 | 11 % | ||||
Europe, the Middle East, and Africa | 67,733 | 58,072 | 982 | 59,054 | 15 % | ||||
Asia Pacific | 17,262 | 16,253 | (1) | 16,252 | 6 % | ||||
Latin America | 10,865 | 8,642 | 140 | 8,782 | 24 % | ||||
Total | $ 195,450 | $ 172,480 | $ 1,114 | $ 173,594 | 13 % | ||||
Artivion, Inc. and Subsidiaries
| |||||||
Three Months Ended | Six Months Ended | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Reconciliation of G&A expense, GAAP to adjusted G&A, non-GAAP: | |||||||
General, administrative, and marketing expense, GAAP | $ 49,320 | $ 57,241 | $ 80,009 | $ 107,606 | |||
Business development, integration, and severance expense (income) | 2,033 | 11,101 | (15,354) | 16,098 | |||
Corporate rebranding expense | — | 69 | — | 218 | |||
Abandonment of CardioGenesis Cardiac laser therapy business | — | 160 | — | 160 | |||
Adjusted G&A, non-GAAP | $ 47,287 | $ 45,911 | $ 95,363 | $ 91,130 | |||
Three Months Ended | Six Months Ended | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Reconciliation of net (loss) income, GAAP to adjusted EBITDA, non-GAAP: | |||||||
Net (loss) income, GAAP | $ (2,121) | $ (3,382) | $ 5,412 | $ (16,914) | |||
Adjustments: | |||||||
Interest expense | 8,304 | 6,356 | 16,130 | 12,452 | |||
Depreciation and amortization expense | 5,891 | 5,767 | 11,800 | 11,501 | |||
Stock-based compensation expense | 4,252 | 3,938 | 7,730 | 7,279 | |||
Income tax (benefit) expense | (306) | 725 | 4,942 | 5,338 | |||
Loss on extinguishment of debt | — | — | 3,669 | — | |||
Loss (gain) on foreign currency revaluation | 943 | (797) | 2,353 | (1,770) | |||
Abandonment of CardioGenesis Cardiac laser therapy business | — | 390 | — | 390 | |||
Corporate rebranding expense | — | 69 | — | 218 | |||
Gain from sale of non-financial assets | — | (14,250) | — | (14,250) | |||
Interest income | (353) | (265) | (727) | (340) | |||
Business development, integration, and severance expense (income) | 2,033 | 15,270 | (15,354) | 20,722 | |||
Adjusted EBITDA, non-GAAP | $ 18,643 | $ 13,821 | $ 35,955 | $ 24,626 | |||
Three Months Ended | Six Months Ended | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Reconciliation of cash flows from operating activities, GAAP to free cash flows, non-GAAP: | |||||||
Net cash flows provided by operating activities | $ 6,135 | $ 6,909 | $ 642 | $ 755 | |||
Capital expenditures | (2,513) | (2,172) | (6,124) | (5,015) | |||
Free cash flows, non-GAAP | $ 3,622 | $ 4,737 | $ (5,482) | $ (4,260) | |||
Artivion Inc. and Subsidiaries | |||||||
Three Months Ended | Six Months Ended | ||||||
2024 | 2023 | 2024 | 2023 | ||||
GAAP: | |||||||
(Loss) income before income taxes | $ (2,427) | $ (2,657) | $ 10,354 | $ (11,576) | |||
Income tax (benefit) expense | (306) | 725 | 4,942 | 5,338 | |||
Net (loss) income | $ (2,121) | $ (3,382) | $ 5,412 | $ (16,914) | |||
Diluted (loss) income per common share | $ (0.05) | $ (0.08) | $ 0.13 | $ (0.41) | |||
Diluted weighted-average common shares outstanding | 41,683 | 40,755 | 42,405 | 40,595 | |||
Reconciliation of (loss) income before income taxes, GAAP to adjusted income, non-GAAP: | |||||||
(Loss) income before income taxes, GAAP: | $ (2,427) | $ (2,657) | $ 10,354 | $ (11,576) | |||
Adjustments: | |||||||
Amortization expense | 3,793 | 3,806 | 7,660 | 7,687 | |||
Loss on extinguishment of debt | — | — | 3,669 | — | |||
Non-cash interest expense | 484 | 464 | 1,064 | 926 | |||
Abandonment of CardioGenesis Cardiac laser therapy business | — | 390 | — | 390 | |||
Corporate rebranding expense | — | 69 | — | 218 | |||
Gain from sale of non-financial assets | — | (14,250) | — | (14,250) | |||
Business development, integration, and severance expense (income) | 2,033 | 15,270 | (15,354) | 20,722 | |||
Adjusted income before income taxes, non-GAAP | 3,883 | 3,092 | 7,393 | 4,117 | |||
Income tax expense calculated at a tax rate of 25% | 970 | 773 | 1,848 | 1,029 | |||
Adjusted net income, non-GAAP | $ 2,913 | $ 2,319 | $ 5,545 | $ 3,088 | |||
Reconciliation of diluted income (loss) per common share, GAAP to adjusted diluted income per common share, non-GAAP: | |||||||
Diluted income (loss) per common share, GAAP: | $ (0.05) | $ (0.08) | $ 0.13 | $ (0.41) | |||
Adjustments: | |||||||
Amortization expense | 0.09 | 0.09 | 0.18 | 0.19 | |||
Loss on extinguishment of debt | — | — | 0.09 | — | |||
Non-cash interest expense | 0.01 | 0.01 | 0.02 | 0.02 | |||
Abandonment of CardioGenesis Cardiac laser therapy business | — | 0.01 | — | 0.01 | |||
Corporate rebranding expense | — | — | — | 0.01 | |||
Gain from sale of non-financial assets | — | (0.34) | — | (0.34) | |||
Business development, integration, and severance expense (income) | 0.05 | 0.37 | (0.36) | 0.50 | |||
Tax effect of non-GAAP adjustments | (0.04) | (0.03) | 0.01 | (0.10) | |||
Effect of 25% tax rate | 0.01 | 0.03 | 0.06 | 0.20 | |||
Adjusted diluted income per common share, non-GAAP | $ 0.07 | $ 0.06 | $ 0.13 | $ 0.08 | |||
Reconciliation of diluted weighted-average common shares outstanding GAAP to diluted weighted-average common shares outstanding, non-GAAP: | |||||||
Diluted weighted-average common shares outstanding, GAAP: | 41,683 | 40,755 | 42,405 | 40,595 | |||
Adjustments: | |||||||
Effect of dilutive stock options and awards | 941 | 419 | — | 444 | |||
Diluted weighted-average common shares outstanding, non-GAAP | 42,624 | 41,174 | 42,405 | 41,039 | |||
Contacts: | |
Artivion | Gilmartin Group LLC |
Lance A. Berry | Brian Johnston / Laine Morgan |
Executive Vice President & | Phone: 332-895-3222 |
Chief Financial Officer | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Phone: 770-419-3355 |
| Last Trade: | US$25.25 |
| Daily Volume: | 89,962 |
| Market Cap: | US$1.060B |
February 15, 2024 January 29, 2024 January 18, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
